This OncLive Insights features two oncologists who specialize in the treatment of Acute Lymphoblastic Leukemia (ALL). They discuss risk assessment, approaches to treatment of both Philadelphia chromosome positive (Ph+) and Ph- ALL, the factors they consider when choosing a treatment setting (community or tertiary academic center), use of MRD in ALL, sequencing therapies in the relapsed/refractory setting, and the role of CAR T-cell therapy in this patient population.
Considerations for using newer, novel-based combination regimens to treat patients with metastatic colorectal cancer based on strategies explored in recent clinical trials.
Key thought leaders in gastrointestinal oncology build a lively discussion on recent clinical trial updates on immuno-oncology-based combinations for the management of patients with metastatic gastric and gastroesophageal junction cancers and the implications for clinical practice.
Key opinion leaders discuss recent updates in treating relapsed or refractory multiple myeloma.
Recommendations for appropriately managing metastatic colorectal cancer with anti-EGFR therapy based on recent changes to cetuximab dosing.
Recommendations for sequencing therapies for triple-class refractory myeloma with options such as selinexor, belantamab mafodotin, or melflufen.
Experts in hematology and medical oncology, Anthony Mato, MD, MSCE, and Lori A. Leslie, MD, discuss the current therapeutic options available for marginal zone lymphoma and follicular lymphoma and provide key insights into how the recent accelerated approval of umbralisib has impacted the treatment landscape.
Experts in gynecologic oncology review key advances in treating advanced endometrial cancer and the promise of combination immunotherapy-based regimens.
Corey S. Cutler, MD, MPH, FRCPC; Yi-Bin Chen, MD; and Haris Ali, MD, review currently available treatment options for acute and chronic GVHD and discuss the management of steroid-refractory disease.
